<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

<sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (<sup>177</sup>Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC)....

Full description

Bibliographic Details
Main Authors: Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Current Oncology
Subjects:
prostate cancer
mCRPC
radioligand therapy
<sup>177</sup>Lu-PSMA-617
<sup>177</sup>Lu vipivotide tetraxetan
Online Access:https://www.mdpi.com/1718-7729/31/3/106

Internet

https://www.mdpi.com/1718-7729/31/3/106

Similar Items